DERMATITIS HERPETIFORMIS WITH CLINICAL EXACERBATION AFTER THE DISCONTINUATION OF ORAL ANOVULATORY USE

  • Carlos Gustavo Carneiro de Castro Dermatologista/Dermatologist, pela Sociedade Brasileira de Dermatologia,Clínica Privada/Private Clinic
  • Caroline Graça Cunha Acadêmica de Medicina/Medical Academic, Universidade Gama Filho (UGF), Rio de Janeiro (RJ), Brasil
  • Christiana Monteiro de Lima Médica Graduada/Medical Graduated, Fundação Técnico Educacional Souza Marques (FTESM), Rio de Janeiro (RJ), Brasil
  • Débora Zattele dos Reis Médica Graduada/Medical Graduated, Universidade Nilton Lins, Manaus (AM), Brasil
  • Deborah Maria Brito Sirio Acadêmica de Medicina/Medical Academic, Universidade Gama Filho (UGF), Rio de Janeiro (RJ), Brasil
  • Fred Bernardes Filho Pós Graduando de Dermatologia/Graduated in Dermatology, no Instituto de Dermatologia Professor Rubem David Azulay da Santa Casa da Misericórdia do Rio de Janeiro (IDPRDA - SCMRJ) - Rio de Janeiro (RJ), Brasil
  • Glaura Tinoco Plata Dermatologista/Dermatologist, pela Sociedade Brasileira de Dermatologia,Clínica Privada/Private Clinic
DOI: https://doi.org/10.29021/spdv.72.2.258
Keywords: Dermatitis herpetiformis, Autoimmunity, Celiac disease

Abstract

Dermatitis herpetiformis is an autoimmune skin disease characterized by symmetrical and pruritic vesicular and papular lesions, that occur with herpetiformis layout. The disease pathogenesis is multifactorial, depending on genetic, environmental and immunological components. There are evidence wich suggest that the hormonal factors may play a role in disease. The authors report the case of a 28 year old female patient with dermatitis herpetiformis and gluten-sensitive enteropathy, whose the skin lesions were exacerbate monthly during the menstrual period after stopping use of oral anovulatory.

Downloads

Download data is not yet available.

References

Hanauer L, Azulay-Abulafia L, Azulay DR, Azulay RD. Buloses. In: Azulay RD, Azulay DR, Azulay-Abulafia L, editors. Dermatologia. Rio de Janeiro: Guanabara Koogan; 2013. p. 242-57.

Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol. 2011; 64(6):1027-33.

Caproni M, Antiga E, Melani L, Fabbri P; Italian Group for Cutaneous Immunopathology. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol. 2009; 23(6):633-8.

Yu SS, Connolly MK, Berger TG, McCalmont TH. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog. J Am Acad Dermatol. 2006; 54(2 Suppl):S58-9.

Spitzweg C, Hofbauer LC, Heufelder AE. Dermatitis herpetiformis cured by hormone replacement for panhypopituitarism. Endocr J 1997; 44:437-40.

Haim S, Friedman-Birnbaum R. Hormonal factors in dermatitis herpetiformis. Report of two cases. Dermatologica. 1972; 145(3):199-202.

Tanriverdi F, Silveira LFG, MacColl GS, Boulloux PMG. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol 2003; 176:293-304.

Mendes FBR, Hissa-Elian A, Abreu MAMM, Gonçalves VS. Review: dermatitis herpetiformis. An Bras Dermatol. 2013; 88(4):604-9.

Cunha PR, Barraviera SR, Trevisan F. Dermatoses bolhosas. In: Rotinas de Diagnóstico e Tratamento da Sociedade Brasileira de Dermatologia. Itapevi: AC Farmacêutica; 2012. p. 196-205.

Leitao EA, Bernhard JD. Perimenstrual nonvesicular dermatitis herpetiformis. J Am Acad Dermatol. 1990; 22(2 Pt 2):331-4.

Published
2014-09-19
How to Cite
de Castro, C. G. C., Cunha, C. G., de Lima, C. M., dos Reis, D. Z., Sirio, D. M. B., Filho, F. B., & Plata, G. T. (2014). DERMATITIS HERPETIFORMIS WITH CLINICAL EXACERBATION AFTER THE DISCONTINUATION OF ORAL ANOVULATORY USE. Journal of the Portuguese Society of Dermatology and Venereology, 72(2), 219-222. https://doi.org/10.29021/spdv.72.2.258
Issue
Vol 72 No 2 (2014): Abril - Junho
Section
Case Reports

All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).